Published in J Immunol on June 15, 2005
Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer | NCT04289792
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 3.93
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29
The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys (2014) 2.28
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res (2014) 2.00
Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2013) 1.94
Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther (2008) 1.78
Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. Clin Cancer Res (2014) 1.53
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol (2012) 1.43
IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol (2010) 1.43
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol (2017) 1.41
The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia (2010) 1.33
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med (2007) 1.33
Radiation-induced effects and the immune system in cancer. Front Oncol (2012) 1.27
Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother (2008) 1.18
PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res (2015) 1.14
Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 1.12
γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One (2011) 1.11
Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol (2015) 1.11
Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol (2012) 1.08
Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 1.07
The confluence of radiotherapy and immunotherapy. Front Oncol (2012) 1.06
Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res (2010) 1.06
The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol (2011) 1.05
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol (2016) 1.05
TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunol Res (2015) 1.03
The effect of radiation on the immune response to cancers. Int J Mol Sci (2014) 1.03
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology (2015) 1.03
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Rep (2014) 1.01
Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol (2012) 1.00
Radiobiological basis of SBRT and SRS. Int J Clin Oncol (2014) 0.99
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res (2015) 0.98
Regulatory T cells in radiotherapeutic responses. Front Oncol (2012) 0.98
Current concepts in clinical radiation oncology. Radiat Environ Biophys (2013) 0.97
Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother (2013) 0.96
CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Front Oncol (2012) 0.95
Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front Oncol (2014) 0.95
Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat Res (2014) 0.95
Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm (2014) 0.95
Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother (2009) 0.94
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92
Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model. Radiat Res (2010) 0.91
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene (2013) 0.91
IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol (2013) 0.91
Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res (2014) 0.90
In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccin Immunother (2015) 0.90
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology (2015) 0.89
Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance. EMBO Mol Med (2014) 0.89
How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol (2012) 0.88
Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J Control Release (2013) 0.88
Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One (2011) 0.88
Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res (2012) 0.88
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res (2015) 0.88
Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery. Radiat Oncol J (2015) 0.87
Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer. World J Gastroenterol (2014) 0.87
Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model. PLoS One (2012) 0.87
The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology (2015) 0.87
T lymphocytes and normal tissue responses to radiation. Front Oncol (2012) 0.86
Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. Int J Cancer (2013) 0.86
Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS One (2012) 0.86
CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J Immunol (2008) 0.86
To ablate or not to ablate? HSCs in the T cell driver's seat. J Clin Invest (2007) 0.86
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med (2014) 0.86
The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells. Inflamm Res (2012) 0.85
Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth. Transl Oncol (2013) 0.85
Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated γ-irradiation. Radiat Oncol (2014) 0.85
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) (2015) 0.85
Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res (2011) 0.84
In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer. Mol Cancer Ther (2012) 0.84
Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Mol Pharm (2011) 0.84
Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. Cancer Immunol Immunother (2012) 0.84
Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR). Breast Cancer (Auckl) (2011) 0.83
Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation. Front Oncol (2016) 0.83
Radiation and immunotherapy: Renewed allies in the war on cancer. Oncoimmunology (2012) 0.83
Local irradiation of murine melanoma affects the development of tumour-specific immunity. Immunology (2009) 0.83
Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther (2010) 0.83
Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model. Clin Immunol (2008) 0.82
Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion. Radiat Res (2014) 0.82
Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines. J Transl Med (2012) 0.81
Transcriptional IL-15-directed in vivo DC targeting DNA vaccine. Gene Ther (2009) 0.81
Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer (2016) 0.81
Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol (2015) 0.80
Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother (2013) 0.80
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol (2011) 0.80
Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer (2016) 0.80
Generation of a dual-functioning antitumor immune response in the peritoneal cavity. Am J Pathol (2013) 0.80
A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol (2006) 12.13
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A (2007) 6.08
Two RNAi complexes, RITS and RDRC, physically interact and localize to noncoding centromeric RNAs. Cell (2004) 4.34
Optimization and use of peptide mass measurement accuracy in shotgun proteomics. Mol Cell Proteomics (2006) 4.25
The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods (2005) 3.71
Large-scale phosphorylation analysis of alpha-factor-arrested Saccharomyces cerevisiae. J Proteome Res (2007) 3.13
Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A (2008) 3.03
Steps in assembly of silent chromatin in yeast: Sir3-independent binding of a Sir2/Sir4 complex to silencers and role for Sir2-dependent deacetylation. Mol Cell Biol (2002) 2.93
A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol Cell Proteomics (2004) 2.58
Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. Sci Signal (2011) 2.33
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A (2005) 2.23
The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J Proteome Res (2008) 2.11
Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol (2008) 1.93
Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol (2008) 1.85
Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation. J Proteome Res (2006) 1.82
Quantitative proteomics reveals a dynamic interactome and phase-specific phosphorylation in the Neurospora circadian clock. Mol Cell (2009) 1.80
INF2 is an endoplasmic reticulum-associated formin protein. J Cell Sci (2009) 1.67
Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol (2006) 1.61
Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol (2009) 1.53
Characterization of mouse spleen cells by subtractive proteomics. Mol Cell Proteomics (2005) 1.51
Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev (2010) 1.46
MMFPh: a maximal motif finder for phosphoproteomics datasets. Bioinformatics (2012) 1.44
Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments. Anal Chem (2011) 1.40
Budding yeast silencing complexes and regulation of Sir2 activity by protein-protein interactions. Mol Cell Biol (2004) 1.37
Absolute quantification of protein and post-translational modification abundance with stable isotope-labeled synthetic peptides. Nat Protoc (2011) 1.34
Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol (2006) 1.34
Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis (2006) 1.32
The majority of the Saccharomyces cerevisiae septin complexes do not exchange guanine nucleotides. J Biol Chem (2003) 1.29
Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol (2007) 1.20
Nuclear import strategies of high risk HPV16 L1 major capsid protein. J Biol Chem (2002) 1.17
Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. PLoS One (2011) 1.13
Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res (2009) 1.11
Imaging of vascular development in early mouse decidua and its association with leukocytes and trophoblasts. Biol Reprod (2012) 1.11
Plk1 regulates the kinesin-13 protein Kif2b to promote faithful chromosome segregation. Mol Biol Cell (2012) 1.10
An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg (2009) 1.10
Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol (2003) 1.09
Insulin-stimulated GLUT4 protein translocation in adipocytes requires the Rab10 guanine nucleotide exchange factor Dennd4C. J Biol Chem (2011) 1.07
Transcriptional interference among the murine beta-like globin genes. Blood (2006) 1.06
Quorum sensing: dynamic response of Pseudomonas aeruginosa to external signals. Trends Microbiol (2006) 1.05
Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition. Structure (2013) 1.03
Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. Chem Biol (2012) 1.01
MacroSEQUEST: efficient candidate-centric searching and high-resolution correlation analysis for large-scale proteomics data sets. Anal Chem (2010) 1.01
Yeast Chfr homologs retard cell cycle at G1 and G2/M via Ubc4 and Ubc13/Mms2-dependent ubiquitination. Cell Cycle (2007) 0.97
Antibody-labeled fluorescence imaging of dendritic cell populations in vivo. J Biomed Opt (2008) 0.97
Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology (2009) 0.97
Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat Res (2009) 0.97
Exposure to ionizing radiation induces the migration of cutaneous dendritic cells by a CCR7-dependent mechanism. J Immunol (2012) 0.97
Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother (2013) 0.96
Cyclooxygenase-2 inhibition attenuates antibody responses against human papillomavirus-like particles. J Immunol (2006) 0.96
The L1 major capsid protein of human papillomavirus type 11 interacts with Kap beta2 and Kap beta3 nuclear import receptors. Virology (2003) 0.95
The Tlo proteins are stoichiometric components of Candida albicans mediator anchored via the Med3 subunit. Eukaryot Cell (2012) 0.95
Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo. Photochem Photobiol (2003) 0.94
Optogenetic control of chemokine receptor signal and T-cell migration. Proc Natl Acad Sci U S A (2014) 0.93
A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine (2010) 0.93
IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol (2013) 0.91
Multisite phosphorylation of the guanine nucleotide exchange factor Cdc24 during yeast cell polarization. PLoS One (2009) 0.90
G-protein-coupled receptor-2-interacting protein-1 is required for endothelial cell directional migration and tumor angiogenesis via cortactin-dependent lamellipodia formation. Arterioscler Thromb Vasc Biol (2013) 0.90
In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method. Transplantation (2007) 0.89
IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol (2010) 0.88
Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres. Virol J (2009) 0.88
Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha. Mol Cancer Ther (2006) 0.88
Tempest: GPU-CPU computing for high-throughput database spectral matching. J Proteome Res (2012) 0.88
Insulin stimulates the phosphorylation of the exocyst protein Sec8 in adipocytes. Biosci Rep (2009) 0.88
Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology (2011) 0.88
Emerging themes in uterine natural killer cell heterogeneity and function. Am J Reprod Immunol (2012) 0.87
Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS. Mol Immunol (2009) 0.87
Single-cell cytokine analysis allows detection of cervical T-cell responses against human papillomavirus type 16 L1 in women infected with genital HPV. J Med Virol (2002) 0.87
Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. Int J Cancer (2013) 0.86
Increasing phosphoproteomic coverage through sequential digestion by complementary proteases. Anal Bioanal Chem (2011) 0.86
Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine (2006) 0.85
Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology (2013) 0.85
Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry (2011) 0.85
Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther (2007) 0.84
Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol (2014) 0.84
Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics (2013) 0.83
An implantable vascularized protein gel construct that supports human fetal hepatoblast survival and infection by hepatitis C virus in mice. PLoS One (2010) 0.83
Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection. Vaccine (2009) 0.83
Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine (2007) 0.82
Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer Immun (2013) 0.82